Carbapenem-resistant Klebsiella pneumoniae infections
Conditions
Interventions
Polymyxin combination therapy group:None
Polymyxin monotherapy group:None
Sponsors
Shandong Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Microbiologically documented infections caused by Carbapenem-resistant Klebsiella pneumoniae ; 2. patients who received intravenous polymyxin (sulfate polymyxin B or colistin methanesulfonate) alone or polymyxin combined with tigecycline for more than 24 hours ; 3. patients aged 18 years or older.
Exclusion criteria
Exclusion criteria: 1. patients who received tigecycline more than 24 hours after or before receiving intravenous polymyxin; 2.patients with missing data more than 20%;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 28-day all-cause mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| The occurrence of acute kidney injury associated with polymyxin;14-day all-cause mortality;14-day CRKP clearance rate;Days of mechanical ventilation within 28 days;Days of renal replacement therapy within 28 days;Length of ICU stay,Total length of hospital stay;Days of vasopressor use within 28 days; | — |
Countries
China
Contacts
Public ContactJuan Zeng
Shandong Provincial Hospital
Outcome results
None listed